Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer
- 1 November 2021
- journal article
- research article
- Published by Elsevier in European Urology Focus
- Vol. 7 (6) , 1287-1291
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (GNT1098647)
- National Health and Medical Research Council (APP1155163)
- Victorian Cancer Agency (CRF14009)
- Monash University
- Cancer Council Tasmania
- Astellas Pharma US
- National Breast Cancer Foundation (ECF-17-001)
This publication has 10 references indexed in Scilit:
- Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancerCancer Medicine, 2020
- Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancerMedicine, 2019
- A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I–III colon cancerEBioMedicine, 2019
- Cell-free DNA in cancer: current insightsCellular Oncology, 2018
- Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)European Urology, 2018
- Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patientsEuropean Journal of Cancer, 2018
- Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell CarcinomaEuropean Urology, 2017
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerJNCI: Journal of the National Cancer Institute, 2017
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerJAMA Oncology, 2016
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerClinical Cancer Research, 2015